Search: onr:"swepub:oai:DiVA.org:uu-440773" >
Antipsychotic use a...
-
Taipale, HeidiKarolinska Institutet
(author)
Antipsychotic use among persons with schizophrenia in Sweden and Finland, trends and differences.
- Article/chapterEnglish2020
Publisher, publication year, extent ...
-
2020-12-17
-
Taylor & Francis,2020
-
electronicrdacarrier
Numbers
-
LIBRIS-ID:oai:DiVA.org:uu-440773
-
https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-440773URI
-
https://doi.org/10.1080/08039488.2020.1854853DOI
-
http://kipublications.ki.se/Default.aspx?queryparsed=id:145427104URI
Supplementary language notes
-
Language:English
-
Summary in:English
Part of subdatabase
Classification
-
Subject category:ref swepub-contenttype
-
Subject category:art swepub-publicationtype
Notes
-
OBJECTIVES: To compare the differences in prevalence of antipsychotic and adjunctive pharmacotherapy use among individuals with schizophrenia between Sweden and Finland during 2006-2016.METHODS: Nationwide register-based data were utilized for constructing two separate cohorts: all persons in Finland with a diagnosis of schizophrenia treated in inpatient care during 1972-2014, and persons in Sweden aged 16-64 with recorded diagnoses of schizophrenia in inpatient or specialized outpatient care, sickness absence or disability pension during 2005-2013. The prevalence of use was assessed as a point prevalence on 31 October each year 2006-2016, based on drug use periods modelled with the PRE2DUP method. In 2016, the Finnish cohort included 37,780 persons and Swedish cohort 25,433 persons.RESULTS: The most commonly used antipsychotic in 2016 was oral olanzapine in both countries (22.7% [95% CI 21.6-22.4] in Finland, 20.9% [20.4-21.4] in Sweden), followed by clozapine which was more frequently used in Finland (22.0%, 21.6-22.4) than in Sweden (14.8%, 14.4-15.3). Long-acting injectable (LAI) use was almost two times more likely in Sweden (21.6%, 95% CI 21.1-22.1) than in Finland (12.8%, 12.5-13.1), a difference which was due to more common use of FG-LAIs in Sweden. A four-fold difference was observed in Z-drugs use (19.9% in Sweden versus 5.0% in Finland).CONCLUSION: Potential explanations for the observed discrepancies include differences in national treatment guidelines, methods of data collection, patient characteristics and/or attitudes towards treatment among both patients and physicians.
Subject headings and genre
Added entries (persons, corporate bodies, meetings, titles ...)
-
Puranen, ArtoDepartment of Forensic Psychiatry, University of Eastern Finland, Niuvanniemi Hospital, Kuopio, Finland.; University of Eastern Finland, School of Pharmacy, Kuopio, Finland.
(author)
-
Mittendorfer-Rutz, EllenorKarolinska Institutet
(author)
-
Tiihonen, JariKarolinska Institutet
(author)
-
Tanskanen, AnttiKarolinska Institutet
(author)
-
Cervenka, SimonKarolinska Institutet(Swepub:uu)simce160
(author)
-
Lähteenvuo, MarkkuDepartment of Forensic Psychiatry, University of Eastern Finland, Niuvanniemi Hospital, Kuopio, Finland.
(author)
-
Karolinska InstitutetDepartment of Forensic Psychiatry, University of Eastern Finland, Niuvanniemi Hospital, Kuopio, Finland.; University of Eastern Finland, School of Pharmacy, Kuopio, Finland.
(creator_code:org_t)
Related titles
-
In:Nordic Journal of Psychiatry: Taylor & Francis75:8, s. 315-3220803-94881502-4725
Internet link
Find in a library
To the university's database